The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up.
about
Systemic Sclerosis and Malignancy: A Review of Current DataLong-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study.Cyclophosphamide for ocular inflammatory diseasesNon-Hodgkin's lymphoma in rheumatoid arthritis.Prognostic significance of paraproteinaemia in rheumatoid arthritis.Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.Cyclophosphamide for the treatment of systemic lupus erythematosus.Combination therapy: the risks of infection and tumor induction.Successful treatment of protein-losing gastroenteropathy with steroid pulse and immunosuppressive therapies in a patient with sjögren syndrome.Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease.Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?Is there truly a risk of lymphoma from biologic therapies?Pulmonary complications: one of the most challenging complications of systemic sclerosis.Association between cancer and immunosuppressive therapy--analysis of selected studies in pemphigus and pemphigoid.Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy.Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold.Oral cyclophosphamide for active scleroderma lung disease: a decision analysis.Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study
P2860
Q26740318-5492821B-0DD6-4657-8BB0-174D318D82B0Q33346685-D41EBCA8-A2D1-4A88-AD18-EC61B4EE7F88Q33478325-9BC532B5-BFC6-4B29-BF2A-399CA3EAC9A1Q33517496-2729B658-648D-4F28-A4F2-CF6887F72C94Q33563567-842B9F71-B712-4705-8324-D677C470CD64Q33563584-42D09DC0-5DE0-4E73-A307-85C91449D613Q33715801-225221DD-DDA9-403B-95FB-108D7F29BA6BQ34226984-E98419E4-A682-41F8-B0D6-70EF3B24642DQ34309757-748C6481-DBF0-49EF-9540-47C1543423F0Q35098526-36512D73-5F92-436E-8C5E-9909E5007881Q35555473-1629255B-8DA8-429D-82F2-64DA32CA4F6FQ35555527-AA1991B2-4713-4562-8B92-98A172B3D644Q35595464-957AD7CF-260D-457D-9B7C-DFDF3D68B55FQ36145795-BFCB94F5-5B56-48FC-9D92-5AA7C94277C9Q36964382-B8F3E5C3-032F-4FEF-91BA-22983789E6DEQ37400338-24A6CFEC-B7C2-49C5-93A0-E6DCEFC7084CQ37504310-4E9E7A42-4711-47DE-A7BE-B9CBA631D0B3Q37798091-5C419DDA-A783-4B6C-99EA-9BF8AE77699AQ42359937-88E63287-4FF8-43CD-B1D7-A25B7DCB3932Q42639047-2114CC1C-DD60-4471-A1E3-94FAE81512FCQ44345637-EA26F16A-FFA5-41C6-BC64-F63015CCFA8DQ46015285-561BDD56-2B40-431E-BC09-857699515CACQ57076696-8E574559-271A-4CE1-B3C9-76F85404061F
P2860
The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up.
description
1983 nî lūn-bûn
@nan
1983 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1983 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
name
The occurrence of malignancies ...... olled retrospective follow-up.
@ast
The occurrence of malignancies ...... olled retrospective follow-up.
@en
The occurrence of malignancies ...... olled retrospective follow-up.
@nl
type
label
The occurrence of malignancies ...... olled retrospective follow-up.
@ast
The occurrence of malignancies ...... olled retrospective follow-up.
@en
The occurrence of malignancies ...... olled retrospective follow-up.
@nl
prefLabel
The occurrence of malignancies ...... olled retrospective follow-up.
@ast
The occurrence of malignancies ...... olled retrospective follow-up.
@en
The occurrence of malignancies ...... olled retrospective follow-up.
@nl
P2093
P2860
P356
P1476
The occurrence of malignancies ...... olled retrospective follow-up.
@en
P2093
Boersma JW
Hartman AP
Vandenbroucke JP
P2860
P304
P356
10.1136/ARD.42.4.368
P407
P577
1983-08-01T00:00:00Z